Management of rare side effects of peginterferon and ribavirin therapy during hepatitis C treatment: a case report
نویسندگان
چکیده
Cardiac arrhythmias and syncope are rare consequence of therapy with pegylated interferon. We report a 55-year-old Egyptian woman who developed palpitation and syncopal attacks twice within 3 months after starting therapy with pegylated interferon alpha2b and ribavirin for the treatment of chronic hepatitis C virus. Hepatitis C virus-RNA was undetectable after 12 week. The electrocardiogram holter revealed ventricular extra-systoles on top of sinus tachycardia. pegylated interferon alpha2b therapy was continued but with a reduced dose. Close follow up revealed neither palpitation nor syncope and hepatitis C virus-RNA was undetectable at 24 and 48 weeks of treatment. In conclusion, our study suggests readjustment of the dose of pegylated interferon alpha2b therapy to avoid these serious side effects.
منابع مشابه
Severe muscle weakness during treatment with pegylated interferon alfa for chronic hepatitis C virus infection A rare complication
Background: Interferons (IFNs) are common therapeutics for several diseases such as viral hepatitis, multiple sclerosis and malignancy. A variety of autoimmune related side effects have been observed during IFN therapy. Rare cases of myopathy, polymyositis or dermatomyositis have been reported during therapy with high doses of IFN^5. Case Presentation: In this report, we describe a case with se...
متن کاملCutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C
The treatment of chronic hepatitis C (CHC) has evolved in the past 15 years and combination of pegylated interferon plus ribavirin is its current standard therapy. However, several side effects are commonly observed and frequently lead to transient or definitive interruption of treatment. Although sarcoidosis in its systemic or cutaneous form is a very rare side effect in such circumstances, so...
متن کاملA MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF HEBER ON (INTERFERON ALFA-2b) IN COMBINATION WITH RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C IN IRAN
ABSTRACT Background: Combination therapy with interferon and ribavirin is the most effective treatment for chronic hepatitis C today. The aim of this study was to evaluate the efficacy and safety of thrice-weekly Heberon (interferon alfa-2b) in combination with ribavirin as first -line treatment of chronic hepatitis C. Methods: A total of97 treatment-naive patients received Heberon three milli...
متن کاملThe Development of Cold-type Autoimmune Hemolytic Anemia during Peginterferon alfa-2a plus Ribavirin Treatment in Chronic Hepatitis C Patient: a Case Report
Peginterferon-alfa 2a or alfa 2b plus ribavirin is the treatment of choice in chronic hepatitis C. Severe adverse effects may compromise efficacy of this regiment. There are few reports of warm autoimmune hemolytic anemia following interferon-alfa or peginterferon-alfa2b plus ribavirin treatment. This present report discusses autoimmune hemolytic anemia which developed during peginterferon alfa...
متن کاملSide effects of medical therapy for chronic hepatitis C.
The treatment of chronic hepatitis C virus (HCV) has improved greatly over the past decade. Over half of all patients treated with the combination of peginterferon and ribavirin have the opportunity to achieve sustained virologic response. The major factors which interfere with this goal are the side effects of therapy which require that the doses of peginterferon or ribavirin be reduced or tha...
متن کامل